Summary
Zoetis Inc. reported solid financial results for the second quarter and first half of 2016. Revenue increased by 3% year-over-year for the quarter and 4% for the six-month period, driven by operational growth in both the U.S. and International segments. The company saw growth in its in-line products and strong performance from new products like Apoquel®, contributing positively to the top line. Profitability showed a significant improvement, with Net Income Attributable to Zoetis Inc. swinging from a loss of $37 million in Q2 2015 to a gain of $224 million in Q2 2016, and from $128 million in the first half of 2015 to $428 million in the first half of 2016. This improvement was largely due to a substantial reduction in restructuring charges and acquisition-related costs compared to the prior year, alongside favorable product mix and operational efficiencies. The company's strategic initiatives, including the acquisition of Pharmaq and ongoing operational efficiency programs, appear to be contributing to both revenue growth and cost management. While foreign exchange headwinds impacted reported revenue growth, operational performance remained strong. Zoetis maintained a healthy balance sheet, with ample liquidity and compliance with its debt covenants, demonstrating financial stability and the capacity to continue investing in its growth strategies.
Financial Highlights
53 data points| Revenue | $1.21B |
| Cost of Revenue | $399.00M |
| Gross Profit | $809.00M |
| SG&A Expenses | $343.00M |
| Operating Expenses | $897.00M |
| Interest Expense | $41.00M |
| Net Income | $224.00M |
| EPS (Basic) | $0.45 |
| EPS (Diluted) | $0.45 |
| Shares Outstanding (Basic) | 496.30M |
| Shares Outstanding (Diluted) | 498.80M |
Key Highlights
- 1Revenue increased by 3% to $1,208 million for the three months ended July 3, 2016, and by 4% to $2,370 million for the six months ended July 3, 2016, driven by operational growth excluding foreign exchange impacts.
- 2Net income attributable to Zoetis Inc. significantly improved, reporting $224 million for the quarter (compared to a loss of $37 million in Q2 2015) and $428 million for the six months (compared to $128 million in the prior year).
- 3Restructuring charges and certain acquisition-related costs decreased dramatically to a net benefit of $21 million in Q2 2016, from $266 million in Q2 2015, significantly boosting profitability.
- 4The U.S. segment showed robust revenue growth of 10% for the quarter, primarily driven by companion animal products, while the International segment's revenue was flat operationally but benefited from the Pharmaq acquisition.
- 5Cost of sales and SG&A expenses decreased as a percentage of revenue, indicating improved operational efficiency and cost management.
- 6The company continued to invest in R&D, with expenses increasing by 5% for the quarter and 9% for the six months, indicating a commitment to future product development.
- 7Zoetis maintained strong liquidity with $658 million in cash and cash equivalents and a current ratio of 3.20:1 as of July 3, 2016.